Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director · President, CEO, COB · 10% owner | October 06, 2025 | October 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date October 06, 2025 · Filed October 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,497 |
Reported balance
After 2025-10-06 transaction · row 1
1 source rowRow 1 · 2025-10-06 · Grant · Acquired 15,625 · Balance 187,497 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2030-10-08 | Direct | 11,719 |
Reported balance
After 2025-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-06 · Grant · Acquired 11,719 · Balance 11,719 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-08-18 | Direct | 293,479 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 293,479 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 42,059 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 42,059 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 106,762 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 106,762 F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 438,596 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 438,596 F3: The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 791,885 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 791,885 F4: The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2021 Filed Nov 16, 2021 23:07 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,800 | $6.87 | $12,366.00 |
DisclosureSEC source: 0001567619-21-020595 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,218 F2 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 23:07 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,000 | $6.76 | $6,760.00 |
DisclosureSEC source: 0001567619-21-020595 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,418 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.74 to $6.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:30 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 42,059 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019494 · doc1.xml · derivative · entry 4 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,059 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F6 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:30 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 293,479 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019494 · doc1.xml · derivative · entry 3 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,479 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates. F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:30 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 293,479 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0001567619-21-019494 · doc1.xml · derivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F2 · shares: Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021. F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates. F3 · derivative.exercise_date: The option vests to the extent of 146,740 shares on March 18, 2021, 73,370 shares on March 18, 2022 and 73,369 shares on March 18, 2023. F2 · derivative.underlying_shares: Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,173,917,974 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001567619-21-006690 · doc1.xml · derivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,917,974 Underlying: Common Stock · 1,173,917,974 shares Expires 2031-03-18 F3 · derivative.exercise_date: Such shares vest to the extent of 586,958,987 shares on the date of grant, 293,479,494 shares on March 18, 2022 and 293,479,493 shares on March 18, 2023. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 586,958,987 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-006690 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,670,653 F1 · price: Shares received pursuant to a restricted stock unit grant. Vests in three nearly equal annual installments beginning March 18, 2022. F2 · balance_after: Includes 586,958,987 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 195,652,996 shares on each of March 18, 2022 and March 18, 2023 and 195,652,995 shares on March 18, 2024. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | OtherCommon Stock | 18,661,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020268 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,711,666 F1 · kind: Shares acquired from Issuer pursuant to amended joint plan of reorganization of Issuer (the "Plan"). Pursuant to the Plan, 100 shares of common stock were issued for each dollar of allowed unsecured claim. F1 · price: Shares acquired from Issuer pursuant to amended joint plan of reorganization of Issuer (the "Plan"). Pursuant to the Plan, 100 shares of common stock were issued for each dollar of allowed unsecured claim. Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 14,900 | $0.27 | $4,023.00 |
DisclosureSEC source: 0001567619-19-018128 · doc1.xml · nonDerivative · entry 4 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.24 | $600.00 |
DisclosureSEC source: 0001567619-19-018128 · doc1.xml · nonDerivative · entry 3 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,100 Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.23 | $575.00 |
DisclosureSEC source: 0001567619-19-018128 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,600 Read SEC document |
| September 09, 2019 Filed Sep 10, 2019 21:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $0.22 | $22.00 |
DisclosureSEC source: 0001567619-19-018128 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,100 Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 21:05 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 9,900 | $0.27 | $2,672.01 |
DisclosureSEC source: 0001567619-19-018008 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| September 05, 2019 Filed Sep 6, 2019 21:05 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $0.25 | $25.49 |
DisclosureSEC source: 0001567619-19-018008 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 6,200 | $0.28 | $1,736.00 |
DisclosureSEC source: 0001567619-19-017607 · doc1.xml · nonDerivative · entry 3 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 3,700 | $0.27 | $999.00 |
DisclosureSEC source: 0001567619-19-017607 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 21:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $0.26 | $26.00 |
DisclosureSEC source: 0001567619-19-017607 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 22:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 9,900 | $0.25 | $2,475.00 |
DisclosureSEC source: 0001567619-19-017492 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 22:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $0.23 | $23.00 |
DisclosureSEC source: 0001567619-19-017492 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 500,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007660 · doc1.xml · derivative · entry 2 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-15 F2 · price: The reported transaction involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 500,000 | Not disclosed Strike: $1.42 | Not disclosed |
DisclosureSEC source: 0001567619-19-007660 · doc1.xml · derivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2028-10-15 F2 · price: The reported transaction involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020. Read SEC document |
| October 15, 2018 Filed Oct 17, 2018 20:47 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001567619-18-004233 · doc1.xml · derivative · entry 1 ALSTODT LANCE · CIK 0001756228 · EVP and Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-10-15 F1 · derivative.exercise_date: The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.